{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:07:52Z","timestamp":1793840872063,"version":"4.6.1"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s11010-022-04492-3","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T03:29:27Z","timestamp":1655782167000},"page":"69-88","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":235,"title":["Rheumatoid arthritis: advances in treatment strategies"],"prefix":"10.1007","volume":"478","author":[{"given":"Peeyush","family":"Prasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Surbhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmal Kumar","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ved","family":"Chaturvedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9734-3488","authenticated-orcid":false,"given":"Shivani Arora","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"issue":"1","key":"4492_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41413-018-0016-9","volume":"6","author":"Q Guo","year":"2018","unstructured":"Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J (2018) Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res 6(1):1\u20134. https:\/\/doi.org\/10.1038\/s41413-018-0016-9","journal-title":"Bone Res"},{"key":"4492_CR2","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis.Erratum. Lancet 388(10055):2023\u20132038. https:\/\/doi.org\/10.1016\/S0140-6736(16)30173-8. Epub 2016 May. PMID: 27156434.","journal-title":"Lancet Manuscr Rheum Arthritis"},{"issue":"10","key":"4492_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3390\/cells7100161","volume":"7","author":"H-Y Yap","year":"2018","unstructured":"Yap H-Y, Tee S, Wong M, Chow S-K, Peh S-C, Teow S-Y (2018) Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development. Cells 7(10):161. https:\/\/doi.org\/10.3390\/cells7100161","journal-title":"Cells"},{"issue":"2","key":"4492_CR4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s12016-012-8346-7","volume":"45","author":"J Kurk\u00f3","year":"2013","unstructured":"Kurk\u00f3 J, Besenyei T, Laki J, Glant TT, Mikecz K, Szekanecz Z (2013) Genetics of rheumatoid arthritis\u2014a comprehensive review. Clin Rev Allergy Immunol 45(2):170\u2013179. https:\/\/doi.org\/10.1007\/s12016-012-8346-7","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"4492_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.mpmed.2014.02.011","volume":"42","author":"RC Jeffery","year":"2014","unstructured":"Jeffery RC (2014) Clinical features of rheumatoid arthritis. Medicine (United Kingdom) 42(5):231\u2013236. https:\/\/doi.org\/10.1016\/j.mpmed.2014.02.011","journal-title":"Medicine (United Kingdom)"},{"issue":"3","key":"4492_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jbspin.2018.07.004","volume":"86","author":"B Friedman","year":"2019","unstructured":"Friedman B, Cronstein B (2019) Methotrexate mechanism in treatment of rheumatoid arthritis. Jt Bone Spine 86(3):301\u2013307. https:\/\/doi.org\/10.1016\/j.jbspin.2018.07.004","journal-title":"Jt Bone Spine"},{"issue":"3","key":"4492_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier E, D\u00f6rner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16(3):155\u2013166. https:\/\/doi.org\/10.1038\/s41584-020-0372-x","journal-title":"Nat Rev Rheumatol"},{"issue":"18","key":"4492_CR8","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","volume":"77","author":"S Dhillon","year":"2017","unstructured":"Dhillon S (2017) Tofacitinib: a review in rheumatoid arthritis. Drugs 77(18):1987\u20132001. https:\/\/doi.org\/10.1007\/s40265-017-0835-9","journal-title":"Drugs"},{"issue":"7","key":"4492_CR9","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40265-018-0908-4","volume":"78","author":"ZT Al-Salama","year":"2018","unstructured":"Al-Salama ZT, Scott LJ (2018) Baricitinib: a review in rheumatoid arthritis. Drugs 78(7):761\u2013772. https:\/\/doi.org\/10.1007\/s40265-018-0908-4","journal-title":"Drugs"},{"issue":"6","key":"4492_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2217\/imt-2017-0155","volume":"10","author":"S Zhao","year":"2018","unstructured":"Zhao S, Mysler E, Moots RJ (2018) Etanercept for the treatment of rheumatoid arthritis. Immunotherapy 10(6):433\u2013445. https:\/\/doi.org\/10.2217\/imt-2017-0155","journal-title":"Immunotherapy"},{"issue":"1\u20132","key":"4492_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10354-015-0344-y","volume":"165","author":"H Radner","year":"2015","unstructured":"Radner H, Aletaha D (2015) Anti-TNF therapie in der rheumatoiden Arthritis\u2014ein \u00dcberblick. Wien Med Wochenschr 165(1\u20132):3\u20139. https:\/\/doi.org\/10.1007\/s10354-015-0344-y","journal-title":"Wien Med Wochenschr"},{"issue":"1","key":"4492_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-020-02354-1","volume":"22","author":"M Novella-Navarro","year":"2020","unstructured":"Novella-Navarro M, Plasencia C, Tornero C et al (2020) Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis. Arthritis Res Ther 22(1):1\u20138. https:\/\/doi.org\/10.1186\/s13075-020-02354-1","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"4492_CR13","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41584-019-0170-5","volume":"15","author":"R van Vollenhoven","year":"2019","unstructured":"van Vollenhoven R (2019) Treat-to-target in rheumatoid arthritis\u2014are we there yet? Nat Rev Rheumatol 15(3):180\u2013186. https:\/\/doi.org\/10.1038\/s41584-019-0170-5","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"4492_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jajs.2016.07.002","volume":"3","author":"S Arora","year":"2016","unstructured":"Arora S, Rafiq A, Jolly M (2016) Management of rheumatoid arthritis: review of current guidelines. J Arthrosc Jt Surg 3(2):45\u201350. https:\/\/doi.org\/10.1016\/j.jajs.2016.07.002","journal-title":"J Arthrosc Jt Surg"},{"issue":"3","key":"4492_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/1756-185X.13513","volume":"22","author":"CS Lau","year":"2019","unstructured":"Lau CS, Chia F, Dans L et al (2019) 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis 22(3):357\u2013375. https:\/\/doi.org\/10.1111\/1756-185X.13513","journal-title":"Int J Rheum Dis"},{"issue":"9","key":"4492_CR16","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1002\/art.22052","volume":"54","author":"D Aletaha","year":"2006","unstructured":"Aletaha D, Smolen J, Ward MM (2006) Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 54(9):2784\u20132792. https:\/\/doi.org\/10.1002\/art.22052","journal-title":"Arthritis Rheum"},{"issue":"6","key":"4492_CR17","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1136\/ard.2009.114652","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Aletaha D, Grisar JC, Stamm TA, Sharp JT (2010) Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis 69(6):1058\u20131064. https:\/\/doi.org\/10.1136\/ard.2009.114652","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"4492_CR18","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1136\/annrheumdis-2015-208324","volume":"75","author":"D Aletaha","year":"2016","unstructured":"Aletaha D, Alasti F, Smolen JS (2016) Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. Ann Rheum Dis 75(8):1479\u20131485. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208324","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4492_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.rdc.2017.04.003","volume":"43","author":"V van Drongelen","year":"2017","unstructured":"van Drongelen V, Holoshitz J (2017) Human leukocyte antigen-disease associations in rheumatoid arthritis. Rheum Dis Clin North Am 43(3):363\u2013376. https:\/\/doi.org\/10.1016\/j.rdc.2017.04.003","journal-title":"Rheum Dis Clin North Am"},{"issue":"3","key":"4492_CR20","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/ar89","volume":"2","author":"L Fugger","year":"2000","unstructured":"Fugger L, Svejgaard A (2000) Association of MHC and rheumatoid arthritis HLA-DR4 and rheumatoid arthritis: studies in mice and men. Arthritis Res 2(3):208\u2013211. https:\/\/doi.org\/10.1186\/ar89","journal-title":"Arthritis Res"},{"issue":"10","key":"4492_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fgene.2019.00570","volume":"14","author":"MV Nemtsova","year":"2019","unstructured":"Nemtsova MV, Zaletaev DV, Bure IV et al (2019) Epigenetic changes in the pathogenesis of rheumatoid arthritis. Front Genet 14(10):1\u201313. https:\/\/doi.org\/10.3389\/fgene.2019.00570","journal-title":"Front Genet"},{"issue":"1","key":"4492_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-24240-2","volume":"8","author":"E Karouzakis","year":"2018","unstructured":"Karouzakis E, Raza K, Kolling C et al (2018) Analysis of early changes in DNA methylation in synovial fibroblasts of RA patients before diagnosis. Sci Rep 8(1):1\u20136. https:\/\/doi.org\/10.1038\/s41598-018-24240-2","journal-title":"Sci Rep"},{"issue":"6","key":"4492_CR23","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/art.34340","volume":"64","author":"E Karouzakis","year":"2012","unstructured":"Karouzakis E, Gay RE, Gay S, Neidhart M (2012) Increased recycling of polyamines is associated with global DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 64(6):1809\u20131817. https:\/\/doi.org\/10.1002\/art.34340","journal-title":"Arthritis Rheum"},{"issue":"2","key":"4492_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.taap.2013.04.014","volume":"270","author":"S Ahmed","year":"2013","unstructured":"Ahmed S, Riegsecker S, Beamer M et al (2013) Largazole, a class I histone deacetylase inhibitor, enhances TNF-\u03b1-induced ICAM-1 and VCAM-1 expression in rheumatoid arthritis synovial fibroblasts. Toxicol Appl Pharmacol 270(2):87\u201396. https:\/\/doi.org\/10.1016\/j.taap.2013.04.014","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"4492_CR25","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3892\/etm.2015.2635","volume":"10","author":"L Wang","year":"2015","unstructured":"Wang L, Ding Y, Guo X, Zhao Q (2015) Role and mechanism of vascular cell adhesion molecule-1 in the development of rheumatoid arthritis. Exp Ther Med 10(3):1229\u20131233. https:\/\/doi.org\/10.3892\/etm.2015.2635","journal-title":"Exp Ther Med"},{"issue":"1","key":"4492_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-04310-9","volume":"9","author":"R Ai","year":"2018","unstructured":"Ai R, Laragione T, Hammaker D et al (2018) Comprehensive epigenetic landscape of rheumatoid arthritis fibroblast-like synoviocytes. Nat Commun 9(1):1\u20131. https:\/\/doi.org\/10.1038\/s41467-018-04310-9","journal-title":"Nat Commun"},{"issue":"12","key":"4492_CR27","doi-asserted-by":"publisher","first-page":"22279","DOI":"10.3390\/ijms151222279","volume":"15","author":"K Chang","year":"2014","unstructured":"Chang K, Yang SM, Kim SH, Han KH, Park SJ, Il SJ (2014) Smoking and rheumatoid arthritis. Int J Mol Sci 15(12):22279\u201322295. https:\/\/doi.org\/10.3390\/ijms151222279","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4492_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1191\/0748233705th211oa","volume":"21","author":"F Ozguner","year":"2005","unstructured":"Ozguner F, Koyu A, Cesur G (2005) Active smoking causes oxidative stress and decreases blood melatonin levels. Toxicol Ind Health 21(10):21\u201326. https:\/\/doi.org\/10.1191\/0748233705th211oa","journal-title":"Toxicol Ind Health"},{"issue":"6","key":"4492_CR29","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1046\/j.1365-2362.2001.00842.x","volume":"31","author":"M Bijl","year":"2001","unstructured":"Bijl M, Horst G, Limburg PC, Kallenberg CGM (2001) Effects of smoking on activation markers, Fas expression and apoptosis of peripheral blood lymphocytes. Eur J Clin Invest 31(6):550\u2013553. https:\/\/doi.org\/10.1046\/j.1365-2362.2001.00842.x","journal-title":"Eur J Clin Invest"},{"issue":"8","key":"4492_CR30","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1089\/jir.2007.0081","volume":"28","author":"M Shizu","year":"2007","unstructured":"Shizu M, Itoh Y, Sunahara R et al (2007) Cigarette smoke condensate upregulates the gene and protein expression of proinflammatory cytokines in human fibroblast-like synoviocyte line. J Interferon Cytokine Res 28(8):509\u2013521. https:\/\/doi.org\/10.1089\/jir.2007.0081","journal-title":"J Interferon Cytokine Res"},{"issue":"2","key":"4492_CR31","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/0022034511421200","volume":"91","author":"J Lee","year":"2012","unstructured":"Lee J, Taneja V, Vassallo R (2012) Cigarette smoking and inflammation: cellular and molecular mechanisms. J Dent Res 91(2):142\u2013149. https:\/\/doi.org\/10.1177\/0022034511421200","journal-title":"J Dent Res"},{"issue":"12","key":"4492_CR32","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1093\/rheumatology\/keu254","volume":"53","author":"M Xue","year":"2014","unstructured":"Xue M, McKelvey K, Shen K et al (2014) Endogenous MMP-9 and not MMP-2 promotes rheumatoid synovial fibroblast survival, inflammation and cartilage degradation. Rheumatol (United Kingdom) 53(12):2270\u20132279. https:\/\/doi.org\/10.1093\/rheumatology\/keu254","journal-title":"Rheumatol (United Kingdom)"},{"issue":"5","key":"4492_CR33","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/1759720X15598307","volume":"7","author":"A Cribbs","year":"2015","unstructured":"Cribbs A, Feldmann M, Oppermann U (2015) Towards an understanding of the role of DNA methylation in rheumatoid arthritis: therapeutic and diagnostic implications. Ther Adv Musculoskelet Dis 7(5):206\u2013219. https:\/\/doi.org\/10.1177\/1759720X15598307","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"8","key":"4492_CR34","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/art.38634","volume":"66","author":"B Lu","year":"2014","unstructured":"Lu B, Solomon DH, Costenbader KH, Karlson EW (2014) Alcohol consumption and risk of incident rheumatoid arthritis in women: a prospective study. Arthritis Rheumatol 66(8):1998\u20132005. https:\/\/doi.org\/10.1002\/art.38634","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"4492_CR35","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00296-017-3912-1","volume":"38","author":"C Forsyth","year":"2018","unstructured":"Forsyth C, Kouvari M, D\u2019Cunha NM et al (2018) The effects of the mediterranean diet on rheumatoid arthritis prevention and treatment: a systematic review of human prospective studies. Rheumatol Int 38(5):737\u2013747. https:\/\/doi.org\/10.1007\/s00296-017-3912-1","journal-title":"Rheumatol Int"},{"key":"4492_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2017.00052","author":"S Khanna","year":"2017","unstructured":"Khanna S, Jaiswal KS, Gupta B (2017) Managing rheumatoid arthritis with dietary interventions. Front Nutr. https:\/\/doi.org\/10.3389\/fnut.2017.00052","journal-title":"Front Nutr"},{"issue":"6","key":"4492_CR37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/2042018812471070","volume":"3","author":"I Kostoglou-Athanassiou","year":"2012","unstructured":"Kostoglou-Athanassiou I, Athanassiou P, Lyraki A, Raftakis I, Antoniadis C (2012) Vitamin D and rheumatoid arthritis. Ther Adv Endocrinol Metab 3(6):181\u2013187. https:\/\/doi.org\/10.1177\/2042018812471070","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"6","key":"4492_CR38","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrd1109","volume":"2","author":"JS Smolen","year":"2003","unstructured":"Smolen JS, Steiner G (2003) Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2(6):473\u2013488. https:\/\/doi.org\/10.1038\/nrd1109","journal-title":"Nat Rev Drug Discov"},{"key":"4492_CR39","doi-asserted-by":"crossref","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease- modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):S685\u2013S699","DOI":"10.1136\/annrheumdis-2019-216655"},{"issue":"5","key":"4492_CR40","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jbspin.2016.10.010","volume":"84","author":"A Mazouy\u00e8s","year":"2017","unstructured":"Mazouy\u00e8s A, Clay M, Bernard AC, Gaudin P, Baillet A (2017) Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: meta-analysis of randomized controlled trials. Jt Bone Spine 84(5):563\u2013570. https:\/\/doi.org\/10.1016\/j.jbspin.2016.10.010","journal-title":"Jt Bone Spine"},{"issue":"2\u20133","key":"4492_CR41","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0162-3109(00)00191-0","volume":"47","author":"ML Herrmann","year":"2000","unstructured":"Herrmann ML, Schleyerbach R, Kirschbaum BJ (2000) Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 47(2\u20133):273\u2013289. https:\/\/doi.org\/10.1016\/S0162-3109(00)00191-0","journal-title":"Immunopharmacology"},{"issue":"5","key":"4492_CR42","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S1567-5769(01)00186-2","volume":"2","author":"S Hirohata","year":"2002","unstructured":"Hirohata S, Ohshima N, Yanagida T, Aramaki K (2002) Regulation of human B cell function by sulfasalazine and its metabolites. Int Immunopharmacol 2(5):631\u2013640. https:\/\/doi.org\/10.1016\/S1567-5769(01)00186-2","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"4492_CR43","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","volume":"23","author":"KD Rainsford","year":"2015","unstructured":"Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF (2015) Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23(5):231\u2013269. https:\/\/doi.org\/10.1007\/s10787-015-0239-y","journal-title":"Inflammopharmacology"},{"issue":"10","key":"4492_CR44","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1080\/13543784.2017.1372422","volume":"26","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Abdul Azeez M, Kiriakidis S (2017) Filgotinib for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs 26(10):1181\u20131187. https:\/\/doi.org\/10.1080\/13543784.2017.1372422","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"4492_CR45","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2217\/imt-2018-0178","volume":"11","author":"J Jegatheeswaran","year":"2019","unstructured":"Jegatheeswaran J, Turk M, Pope JE (2019) Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review. Immunotherapy 11(8):737\u2013754. https:\/\/doi.org\/10.2217\/imt-2018-0178","journal-title":"Immunotherapy"},{"key":"4492_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-eular.6433","author":"J Bernal","year":"2017","unstructured":"Bernal J, Vela P, Ruiz Garc\u00eda V, Burls A, Cabello J, Bort-Mart\u00ed S (2017) FRI0199 systematic review and meta-analysis on certolizumab pegol for rheumatoid arthritis in adults. Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2017-eular.6433","journal-title":"Rheum Dis"},{"issue":"2","key":"4492_CR47","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3899\/jrheum.160287","volume":"44","author":"G Jones","year":"2017","unstructured":"Jones G, Wallace T, McIntosh MJ, Brockwell L, Gomez-Reino JJ, Sebba A (2017) Five-year efficacy and safety of tocilizumab monotherapy in patients with rheumatoid arthritis who were methotrexate-and biologic-naive or free of methotrexate for 6\u00a0months: the ambition study. J Rheumatol 44(2):142\u2013146. https:\/\/doi.org\/10.3899\/jrheum.160287","journal-title":"J Rheumatol"},{"issue":"3","key":"4492_CR48","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2174\/1574887113666180314102651","volume":"13","author":"P Ruscitti","year":"2018","unstructured":"Ruscitti P, Cipriani P, Liakouli V et al (2018) The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes. Rev Recent Clin Trials 13(3):210\u2013214. https:\/\/doi.org\/10.2174\/1574887113666180314102651","journal-title":"Rev Recent Clin Trials"},{"issue":"11","key":"4492_CR49","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","volume":"77","author":"HA Blair","year":"2017","unstructured":"Blair HA, Deeks ED (2017) Abatacept: a review in rheumatoid arthritis. Drugs 77(11):1221\u20131233. https:\/\/doi.org\/10.1007\/s40265-017-0775-4","journal-title":"Drugs"},{"issue":"1","key":"4492_CR50","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/14712598.2017.1263614","volume":"17","author":"YG Chiu","year":"2017","unstructured":"Chiu YG, Ritchlin CT (2017) Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis. Expert Opin Biol Ther 17(1):119\u2013128. https:\/\/doi.org\/10.1080\/14712598.2017.1263614","journal-title":"Expert Opin Biol Ther"},{"key":"4492_CR51","unstructured":"It T, Effects S. Denosumab (Prolia)"},{"key":"4492_CR52","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/DDDT.S104233","volume":"11","author":"C Crotti","year":"2017","unstructured":"Crotti C, Raimondo MG, Becciolini A, Biggioggero M, Favalli EG (2017) Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. Drug Des Devel Ther 11:211\u2013223. https:\/\/doi.org\/10.2147\/DDDT.S104233","journal-title":"Drug Des Devel Ther"},{"key":"4492_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab917","author":"AA Sherbini","year":"2022","unstructured":"Sherbini AA, Gwinnutt JM, Hyrich KL et al (2022) Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keab917","journal-title":"Rheumatology"},{"key":"4492_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.789334","volume":"12","author":"H Yan","year":"2021","unstructured":"Yan H, Su R, Xue H, Gao C, Li X, Wang C (2021) Pharmacomicrobiology of methotrexate in rheumatoid arthritis: gut microbiome as predictor of therapeutic response. Front Immunol 12:1\u201315. https:\/\/doi.org\/10.3389\/fimmu.2021.789334","journal-title":"Front Immunol"},{"issue":"1","key":"4492_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-018-1645-5","volume":"20","author":"JC Sergeant","year":"2018","unstructured":"Sergeant JC, Hyrich KL, Anderson J et al (2018) Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). Arthritis Res Ther 20(1):1\u201311. https:\/\/doi.org\/10.1186\/s13075-018-1645-5","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"4492_CR56","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/art.41622","volume":"73","author":"A Artacho","year":"2021","unstructured":"Artacho A, Isaac S, Nayak R et al (2021) The pretreatment gut microbiome is associated with lack of response to methotrexate in new-onset rheumatoid arthritis. Arthritis Rheumatol 73(6):931\u2013942. https:\/\/doi.org\/10.1002\/art.41622","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"4492_CR57","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3899\/jrheum.180537","volume":"46","author":"K Hambardzumyan","year":"2019","unstructured":"Hambardzumyan K, Bolce RJ, Wallman JK, Van Vollenhoven RF, Saevarsdottir S (2019) Serum biomarkers for prediction of response to methotrexate monotherapy in early rheumatoid arthritis: results from the SWEFOT trial. J Rheumatol 46(6):555\u2013563. https:\/\/doi.org\/10.3899\/jrheum.180537","journal-title":"J Rheumatol"},{"key":"4492_CR58","doi-asserted-by":"publisher","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","volume":"58","author":"GE Fragoulis","year":"2019","unstructured":"Fragoulis GE, Mcinnes IB, Siebert S (2019) JAK-inhibitors. new players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (United Kingdom) 58:i43\u2013i54","journal-title":"Rheumatology (United Kingdom)"},{"issue":"1","key":"4492_CR59","doi-asserted-by":"publisher","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","volume":"58","author":"M Harigai","year":"2019","unstructured":"Harigai M (2019) Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (United Kingdom) 58(1):i34\u2013i42. https:\/\/doi.org\/10.1093\/rheumatology\/key287","journal-title":"Rheumatology (United Kingdom)"},{"issue":"4","key":"4492_CR60","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMoa1310476","volume":"21","author":"R Lunzer","year":"2014","unstructured":"Lunzer R (2014) Tofacitinib versus methotrexate in rheumatoid arthritis: kommentar. J Miner 21(4):157. https:\/\/doi.org\/10.1056\/NEJMoa1310476","journal-title":"J Miner"},{"issue":"10093","key":"4492_CR61","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S et al (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390(10093):457\u2013468. https:\/\/doi.org\/10.1016\/S0140-6736(17)31618-5","journal-title":"Lancet"},{"issue":"9","key":"4492_CR62","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1177\/1060028019839650","volume":"53","author":"A Mogul","year":"2019","unstructured":"Mogul A, Corsi K, McAuliffe L (2019) Baricitinib: the second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 53(9):947\u2013953. https:\/\/doi.org\/10.1177\/1060028019839650","journal-title":"Ann Pharmacother"},{"issue":"2","key":"4492_CR63","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40744-021-00423-8","volume":"9","author":"B Hern\u00e1ndez-Cruz","year":"2022","unstructured":"Hern\u00e1ndez-Cruz B, Rosas J, D\u00edaz-Torn\u00e9 C et al (2022) Real-world treatment patterns and clinical outcomes of baricitinib in rheumatoid arthritis patients in spain: results of a multicenter, observational study in routine clinical practice (The ORBIT-RA Study). Rheumatol Ther 9(2):589\u2013608. https:\/\/doi.org\/10.1007\/s40744-021-00423-8","journal-title":"Rheumatol Ther"},{"issue":"3","key":"4492_CR64","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","volume":"81","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, Takeuchi T, Burmester GR et al (2022) Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3\u00a0years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis 81(3):335\u2013343. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221276","journal-title":"Ann Rheum Dis"},{"key":"4492_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2021.764067","volume":"8","author":"Y Kaneko","year":"2022","unstructured":"Kaneko Y, Murakami T, Nishitsuka K, Takakubo Y, Takagi M, Yamashita H (2022) Effectiveness of baricitinib in refractory seronegative rheumatoid arthritis and uveitis: a case report. Front Med 8:1\u20136. https:\/\/doi.org\/10.3389\/fmed.2021.764067","journal-title":"Front Med"},{"issue":"6","key":"4492_CR66","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","volume":"76","author":"R Westhovens","year":"2017","unstructured":"Westhovens R, Taylor PC, Alten R et al (2017) Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis 76(6):998\u20131008. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210104","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4492_CR67","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","volume":"80","author":"R Westhovens","year":"2021","unstructured":"Westhovens R, Rigby WFC, Van Der Heijde D et al (2021) Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis 80(6):727\u2013738. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219213","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"4492_CR68","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.3899\/jrheum.201183","volume":"48","author":"A Kavanaugh","year":"2021","unstructured":"Kavanaugh A, Westhovens RR, Winthrop KL et al (2021) Safety and efficacy of filgotinib: Up to 4-year results from an open-label extension study of phase II rheumatoid arthritis programs. J Rheumatol 48(8):1230\u20131238. https:\/\/doi.org\/10.3899\/jrheum.201183","journal-title":"J Rheumatol"},{"issue":"2","key":"4492_CR69","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1136\/annrheumdis-2021-221051","volume":"81","author":"KL Winthrop","year":"2022","unstructured":"Winthrop KL, Tanaka Y, Takeuchi T et al (2022) Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6\u00a0years. Ann Rheum Dis 81(2):184\u2013192. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221051","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4492_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/rmdopen-2021-002012","volume":"8","author":"R Fleischmann","year":"2022","unstructured":"Fleischmann R, Mysler E, Bessette L et al (2022) Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3\u00a0years from the SELECT-COMPARE study. RMD Open 8(1):1\u201312. https:\/\/doi.org\/10.1136\/rmdopen-2021-002012","journal-title":"RMD Open"},{"issue":"1","key":"4492_CR71","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40744-021-00399-5","volume":"9","author":"P Conaghan","year":"2022","unstructured":"Conaghan P, Cohen S, Burmester G et al (2022) Benefit-risk analysis of upadacitinib compared with adalimumab in the treatment of patients with moderate-to-severe rheumatoid arthritis. Rheumatol Ther 9(1):191\u2013206. https:\/\/doi.org\/10.1007\/s40744-021-00399-5","journal-title":"Rheumatol Ther"},{"issue":"7","key":"4492_CR72","first-page":"5","volume":"36","author":"AE Koch","year":"2007","unstructured":"Koch AE (2007) The pathogenesis of rheumatoid arthritis. Am J Orthop (Belle Mead NJ) 36(7):5\u20138","journal-title":"Am J Orthop (Belle Mead NJ)"},{"issue":"2","key":"4492_CR73","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0306-4530(94)90010-8","volume":"19","author":"FJ Tilders","year":"1994","unstructured":"Tilders FJ, DeRuk RH, Van Dam AM, Vincent VA, Schotanus K, Persoons JH (1994) Activation of the hypothalamus-pituitary-adrenal axis by bacterial endotoxins: routes and intermediate signals. Psychoneuroendocrinology 19(2):209\u2013232","journal-title":"Psychoneuroendocrinology"},{"issue":"10","key":"4492_CR74","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1002\/eji.1830211039","volume":"21","author":"C Haworth","year":"1991","unstructured":"Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M (1991) Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-\u03b1. Eur J Immunol 21(10):2575\u20132579. https:\/\/doi.org\/10.1002\/eji.1830211039","journal-title":"Eur J Immunol"},{"issue":"19","key":"4492_CR75","doi-asserted-by":"publisher","first-page":"7547","DOI":"10.1073\/pnas.86.19.7547","volume":"86","author":"S Suematsu","year":"1989","unstructured":"Suematsu S, Matsuda T, Aozasa K et al (1989) IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 86(19):7547\u20137551. https:\/\/doi.org\/10.1073\/pnas.86.19.7547","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"4492_CR76","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00296-009-0953-0","volume":"30","author":"M Suzuki","year":"2010","unstructured":"Suzuki M, Hashizume M, Yoshida H, Mihara M (2010) Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule. Rheumatol Int 30(3):309\u2013315. https:\/\/doi.org\/10.1007\/s00296-009-0953-0","journal-title":"Rheumatol Int"},{"issue":"5","key":"4492_CR77","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.semarthrit.2005.01.004","volume":"34","author":"I Nestorov","year":"2005","unstructured":"Nestorov I (2005) Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 34(5):12\u201318. https:\/\/doi.org\/10.1016\/j.semarthrit.2005.01.004","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"4492_CR78","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1517\/14712598.6.12.1349","volume":"6","author":"PV Voulgari","year":"2006","unstructured":"Voulgari PV, Drosos AA (2006) Adalimumab for rheumatoid arthritis. Expert Opin Biol Ther 6(12):1349\u20131360. https:\/\/doi.org\/10.1517\/14712598.6.12.1349","journal-title":"Expert Opin Biol Ther"},{"key":"4492_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.814429","volume":"13","author":"B He","year":"2022","unstructured":"He B, Li Y, Luo W et al (2022) The risk of adverse effects of TNF-\u03b1 inhibitors in patients with rheumatoid arthritis: a network meta-analysis. Front Immunol 13:1\u201316. https:\/\/doi.org\/10.3389\/fimmu.2022.814429","journal-title":"Front Immunol"},{"key":"4492_CR80","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.vhri.2021.06.012","volume":"28","author":"T Hirose","year":"2022","unstructured":"Hirose T, Kawaguchi I, Murata T, Atsumi T (2022) Cost-effectiveness analysis of etanercept 25 mg maintenance therapy after treatment with etanercept 50 mg for moderate rheumatoid arthritis in the PRESERVE trial in japan. Value Heal Reg Issues 28:105\u2013111. https:\/\/doi.org\/10.1016\/j.vhri.2021.06.012","journal-title":"Value Heal Reg Issues"},{"key":"4492_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.795912","volume":"12","author":"Y Cai","year":"2022","unstructured":"Cai Y, Xu K, Aihaiti Y et al (2022) Derlin-1, as a potential early predictive biomarker for nonresponse to infliximab treatment in rheumatoid arthritis is related to autophagy. Front Immunol 12:1\u201315. https:\/\/doi.org\/10.3389\/fimmu.2021.795912","journal-title":"Front Immunol"},{"issue":"1","key":"4492_CR82","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1038\/s41467-018-05044-4","volume":"9","author":"S Tasaki","year":"2018","unstructured":"Tasaki S, Suzuki K, Kassai Y et al (2018) Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission. Nat Commun 9(1):2755. https:\/\/doi.org\/10.1038\/s41467-018-05044-4","journal-title":"Nat Commun"},{"issue":"3","key":"4492_CR83","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/jcm8030387","volume":"8","author":"E Pelechas","year":"2019","unstructured":"Pelechas E, Voulgari PV, Drosos AA (2019) Golimumab for rheumatoid arthritis. J Clin Med 8(3):387. https:\/\/doi.org\/10.3390\/jcm8030387","journal-title":"J Clin Med"},{"issue":"3","key":"4492_CR84","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1517\/17425255.2016.1146682","volume":"12","author":"Y Tanaka","year":"2016","unstructured":"Tanaka Y, Senoo A, Fujii H, Baker D (2016) Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis. Expert Opin Drug Metab Toxicol 12(3):319\u2013326. https:\/\/doi.org\/10.1517\/17425255.2016.1146682","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"4492_CR85","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s40744-022-00424-1","volume":"9","author":"X Theunssens","year":"2022","unstructured":"Theunssens X, Bricman L, Dierckx S et al (2022) Anti-TNF induced sarcoidosis-like disease in rheumatoid arthritis patients: review cases from the RA UCLouvain brussels cohort. Rheumatol Ther 9(2):763\u2013770. https:\/\/doi.org\/10.1007\/s40744-022-00424-1","journal-title":"Rheumatol Ther"},{"key":"4492_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2022.839206","volume":"9","author":"JW Park","year":"2022","unstructured":"Park JW, Kim MJ, Kim H-A, Kim JH, Lee EB, Shin K (2022) The aftermath of tapering tocilizumab after achieving treatment target in patients with rheumatoid arthritis: a nationwide cohort study. Front Med 9:1\u20139. https:\/\/doi.org\/10.3389\/fmed.2022.839206","journal-title":"Front Med"},{"issue":"1","key":"4492_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/rap\/rkac002","volume":"6","author":"H-P Tony","year":"2022","unstructured":"Tony H-P, Feist E, Aries PM et al (2022) Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in Germany. Rheumatol Adv Pract 6(1):1\u20137. https:\/\/doi.org\/10.1093\/rap\/rkac002","journal-title":"Rheumatol Adv Pract"},{"issue":"10271","key":"4492_CR88","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","volume":"397","author":"F Humby","year":"2021","unstructured":"Humby F, Durez P, Buch MH et al (2021) Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet 397(10271):305\u2013317. https:\/\/doi.org\/10.1016\/S0140-6736(20)32341-2","journal-title":"Lancet"},{"issue":"1\u20132","key":"4492_CR89","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","volume":"180","author":"AH Cross","year":"2006","unstructured":"Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA (2006) Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 180(1\u20132):63\u201370. https:\/\/doi.org\/10.1016\/j.jneuroim.2006.06.029","journal-title":"J Neuroimmunol"},{"issue":"10","key":"4492_CR90","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1136\/annrheumdis-2018-214898","volume":"78","author":"S Pollastro","year":"2019","unstructured":"Pollastro S, Klarenbeek PL, Doorenspleet ME et al (2019) Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire. Ann Rheum Dis 78(10):1339\u20131345. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214898","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4492_CR91","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/rheumatology\/key036","volume":"57","author":"AGS Oldroyd","year":"2018","unstructured":"Oldroyd AGS, Symmons DPM, Sergeant JC et al (2018) Long-term persistence with rituximab in patients with rheumatoid arthritis. Rheumatology (United Kingdom) 57(6):1089\u20131096. https:\/\/doi.org\/10.1093\/rheumatology\/key036","journal-title":"Rheumatology (United Kingdom)"},{"issue":"8","key":"4492_CR92","doi-asserted-by":"publisher","first-page":"e19193","DOI":"10.1097\/MD.0000000000019193","volume":"99","author":"Z Wang","year":"2020","unstructured":"Wang Z, Bao HW, Ji Y, Li Y (2020) A systematic review and meta-analysis of rituximab combined with methotrexate versus methotrexate alone in the treatment of rheumatoid arthritis. Medicine (United States) 99(8):e19193. https:\/\/doi.org\/10.1097\/MD.0000000000019193","journal-title":"Medicine (United States)"},{"issue":"2","key":"4492_CR93","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/rheumatology\/keab248","volume":"61","author":"C Norris-Grey","year":"2022","unstructured":"Norris-Grey C, Cambridge G, Moore S, Reddy V, Leandro M (2022) Long-term persistence of rituximab in patients with rheumatoid arthritis: an evaluation of the UCL cohort from 1998 to 2020. Rheumatology (Oxford) 61(2):591\u2013596. https:\/\/doi.org\/10.1093\/rheumatology\/keab248","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"4492_CR94","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.1093\/rheumatology\/keab153","volume":"60","author":"F Behrens","year":"2021","unstructured":"Behrens F, Koehm M, Rossmanith T et al (2021) Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study). Rheumatology 60(11):5318\u20135328. https:\/\/doi.org\/10.1093\/rheumatology\/keab153","journal-title":"Rheumatology"},{"issue":"3","key":"4492_CR95","first-page":"200","volume":"70","author":"JU Scher","year":"2012","unstructured":"Scher JU (2012) B-cell therapies for rheumatoid arthritis. Bull NYU Hosp Jt Dis 70(3):200\u2013203","journal-title":"Bull NYU Hosp Jt Dis"},{"issue":"8","key":"4492_CR96","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1002\/art.21206","volume":"52","author":"RQ Cron","year":"2005","unstructured":"Cron RQ (2005) Editorial: a signal achievement in the treatment of arthritis. Arthritis Rheum 52(8):2229\u20132232. https:\/\/doi.org\/10.1002\/art.21206","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4492_CR97","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/1744666X.2019.1579642","volume":"15","author":"M Pombo-Suarez","year":"2019","unstructured":"Pombo-Suarez M, Gomez-Reino JJ (2019) Abatacept for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 15(4):319\u2013326. https:\/\/doi.org\/10.1080\/1744666X.2019.1579642","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"4492_CR98","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1002\/art.21201","volume":"52","author":"JM Kremer","year":"2005","unstructured":"Kremer JM, Dougados M, Emery P et al (2005) Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52(8):2263\u20132271. https:\/\/doi.org\/10.1002\/art.21201","journal-title":"Arthritis Rheum"},{"issue":"3","key":"4492_CR99","doi-asserted-by":"publisher","first-page":"E358","DOI":"10.1097\/MJT.0000000000000645","volume":"26","author":"T Pascart","year":"2019","unstructured":"Pascart T, Philippe P, Drumez E et al (2019) Abatacept monotherapy versus abatacept plus methotrexate for treatment-refractory rheumatoid arthritis. Am J Ther 26(3):E358\u2013E363. https:\/\/doi.org\/10.1097\/MJT.0000000000000645","journal-title":"Am J Ther"},{"issue":"3","key":"4492_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/mr\/roab090","volume":"32","author":"N Tamura","year":"2021","unstructured":"Tamura N, Azuma T, Misaki K et al (2021) Effectiveness and safety of subcutaneous abatacept in biologic-na\u00efve RA patients at Week 52: a japanese multicentre investigational study (ORIGAMI study). Mod Rheumatol 32(3):1\u201311. https:\/\/doi.org\/10.1093\/mr\/roab090","journal-title":"Mod Rheumatol"},{"issue":"3","key":"4492_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/mr\/roab029","volume":"32","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Matsubara T, Hashizume K, Amano N, Takeuchi T (2021) Efficacy and safety of abatacept in biologic-na\u00efve patients with active rheumatoid arthritis by background methotrexate dose: post hoc analysis of a randomized, placebo-controlled, phase 4 study. Mod Rheumatol 32(3):1\u20138. https:\/\/doi.org\/10.1093\/mr\/roab029","journal-title":"Mod Rheumatol"},{"issue":"7","key":"4492_CR102","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/annrheumdis-2018-214827","volume":"78","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi T, Tanaka Y, Soen S et al (2019) Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase. Ann Rheum Dis 78(7):899\u2013907. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214827","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4492_CR103","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/mr\/roab102","volume":"32","author":"S Tanaka","year":"2022","unstructured":"Tanaka S, Kobayashi M, Saito K, Takita A (2022) Correction to: impact of denosumab discontinuation on changes in bone mineral density and bone erosion in rheumatoid arthritis patients. Mod Rheumatol 32(2):292\u2013295. https:\/\/doi.org\/10.1093\/mr\/roab102","journal-title":"Mod Rheumatol"},{"issue":"1","key":"4492_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.47176\/mjiri.35.12","volume":"35","author":"A Mirzaei","year":"2021","unstructured":"Mirzaei A, Jahed SA, Kadijani AA, Zabihiyeganeh M (2021) Risk of infection in postmenopausal women with rheumatoid arthritis and osteoporosis taking denosumab and bDMARDS. Med J Islam Repub Iran 35(1):1\u20134. https:\/\/doi.org\/10.47176\/mjiri.35.12","journal-title":"Med J Islam Repub Iran"},{"issue":"10188","key":"4492_CR105","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P et al (2019) Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 393(10188):2303\u20132311. https:\/\/doi.org\/10.1016\/S0140-6736(19)30419-2","journal-title":"Lancet"},{"issue":"2","key":"4492_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/rmdopen-2019-001040","volume":"5","author":"V Strand","year":"2019","unstructured":"Strand V, Mysler E, Moots RJ et al (2019) Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB\/IV trial. RMD Open 5(2):1\u201310. https:\/\/doi.org\/10.1136\/rmdopen-2019-001040","journal-title":"RMD Open"},{"key":"4492_CR107","unstructured":"NCT01202760. A Rheumatoid Arthritis Study in Participants [Internet], 2010. http:\/\/cochranelibrarywiley.com\/o\/cochrane\/clcentral\/articles\/205\/CN-01524205\/frame.html"},{"issue":"6","key":"4492_CR108","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/art.40444","volume":"70","author":"ME Weinblatt","year":"2018","unstructured":"Weinblatt ME, Baranauskaite A, Dokoupilova E et al (2018) Switching from reference adalimumab to SB5 (Adalimumab Biosimilar) in Patients With rheumatoid arthritis: fifty-two\u2013week phase III randomized study results. Arthritis Rheumatol 70(6):832\u2013840. https:\/\/doi.org\/10.1002\/art.40444","journal-title":"Arthritis Rheumatol"},{"key":"4492_CR109","unstructured":"A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthri- tis (RAPID-C), NCT02151851. 2018."},{"key":"4492_CR110","unstructured":"Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus\nMethotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate."},{"issue":"2","key":"4492_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/rmdopen-2017-000465","volume":"3","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Kaeley GS, Kavanaugh AF et al (2017) Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. RMD Open 3(2):1\u20139. https:\/\/doi.org\/10.1136\/rmdopen-2017-000465","journal-title":"RMD Open"},{"issue":"1","key":"4492_CR112","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/annrheumdis-2014-205489","volume":"74","author":"P Verschueren","year":"2015","unstructured":"Verschueren P, De Cock D, Corluy L et al (2015) Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16\u00a0weeks of treatment: the CareRA trial. Ann Rheum Dis 74(1):27\u201334. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205489","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"4492_CR113","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1007\/s10067-019-04595-1","volume":"38","author":"Y Huang","year":"2019","unstructured":"Huang Y, Fan Y, Liu Y, Xie W, Zhang Z (2019) Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials. Clin Rheumatol 38(10):2765\u20132776. https:\/\/doi.org\/10.1007\/s10067-019-04595-1","journal-title":"Clin Rheumatol"},{"key":"4492_CR114","doi-asserted-by":"publisher","DOI":"10.1177\/1759720x19831151","author":"L Bessette","year":"2019","unstructured":"Bessette L, Haraoui B, Chow A et al (2019) Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in canadian practice: 2-year results from the observational F\u03b1sT-CAN study. Ther Adv Musculoskelet Dis. https:\/\/doi.org\/10.1177\/1759720x19831151","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"4492_CR115","first-page":"9","volume":"68","author":"V Strand","year":"2016","unstructured":"Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M (2016) Economic burden of non-responders to biologic DMARD treatments in rheumatoid arthritis. Arthritis Rheumatol 68:9\u201310","journal-title":"Arthritis Rheumatol"},{"key":"4492_CR116","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-015-0100-6","author":"TM Thomson","year":"2015","unstructured":"Thomson TM, Lescarbeau RM, Drubin DA et al (2015) Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis. BMC Med Genomics. https:\/\/doi.org\/10.1186\/s12920-015-0100-6","journal-title":"BMC Med Genomics"},{"issue":"1","key":"4492_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-020-2137-y","volume":"22","author":"W Yokoyama-Kokuryo","year":"2020","unstructured":"Yokoyama-Kokuryo W, Yamazaki H, Takeuchi T et al (2020) Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis. Arthritis Res Ther 22(1):1\u20138. https:\/\/doi.org\/10.1186\/s13075-020-2137-y","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"4492_CR118","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1186\/ar3819","volume":"14","author":"HG Raterman","year":"2012","unstructured":"Raterman HG, Vosslamber S, de Ridder S et al (2012) The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther 14(2):R95. https:\/\/doi.org\/10.1186\/ar3819","journal-title":"Arthritis Res Ther"},{"key":"4492_CR119","doi-asserted-by":"publisher","first-page":"S618","DOI":"10.1002\/art.38216%0A","volume":"65","author":"EL Kneepkens","year":"2013","unstructured":"Kneepkens EL, Pascual-Salcedo D, Plasencia C et al (2013) Golimumab levels, anti-drug antibodies and clinical response in rheumatoid arthritis Patients at 28\u00a0week of follow-up: 1456. Arthritis Rheum 65:S618\u2013S619. https:\/\/doi.org\/10.1002\/art.38216%0A","journal-title":"Arthritis Rheum"},{"key":"4492_CR120","volume-title":"Disease modifying anti-rheumatic drugs (DMARD)","author":"O Benjamin","year":"2021","unstructured":"Benjamin O, Bansal P, Goyal A, Lappin SL (2021) Disease modifying anti-rheumatic drugs (DMARD). StatPearls Publishing, Treasure Island"},{"issue":"1","key":"4492_CR121","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.semarthrit.2017.01.004","volume":"47","author":"SK Cho","year":"2017","unstructured":"Cho SK, Kim D, Won S et al (2017) Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment. Semin Arthritis Rheum 47(1):102\u2013107. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.01.004","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"4492_CR122","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s13365-018-0615-7","volume":"24","author":"JR Berger","year":"2018","unstructured":"Berger JR, Malik V, Lacey S, Brunetta P, Lehane PB (2018) Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. J Neurovirol 24(3):323\u2013331. https:\/\/doi.org\/10.1007\/s13365-018-0615-7","journal-title":"J Neurovirol"},{"issue":"2","key":"4492_CR123","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3109\/08916934.2015.1134511","volume":"49","author":"S Aslani","year":"2016","unstructured":"Aslani S, Mahmoudi M, Karami J, Jamshidi AR, Malekshahi Z, Nicknam MH (2016) Epigenetic alterations underlying autoimmune diseases. Autoimmunity 49(2):69\u201383. https:\/\/doi.org\/10.3109\/08916934.2015.1134511","journal-title":"Autoimmunity"},{"issue":"9","key":"4492_CR124","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1002\/art.23758","volume":"58","author":"CJ Nile","year":"2008","unstructured":"Nile CJ, Read RC, Akil M, Duff GW, Wilson AG (2008) Methylation status of a single CpG site in the IL6 promoter is related to IL6 messenger RNA levels and rheumatoid arthritis. Arthritis Rheum 58(9):2686\u20132693. https:\/\/doi.org\/10.1002\/art.23758","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4492_CR125","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/art.22512","volume":"56","author":"LC Huber","year":"2007","unstructured":"Huber LC, Brock M, Hemmatazad H et al (2007) Histone deacetylase\/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum 56(4):1087\u20131093. https:\/\/doi.org\/10.1002\/art.22512","journal-title":"Arthritis Rheum"},{"issue":"3","key":"4492_CR126","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1136\/ard.2011.154211","volume":"71","author":"AM Grabiec","year":"2012","unstructured":"Grabiec AM, Korchynskyi O, Tak PP, Reedquist KA (2012) Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis 71(3):424\u2013431. https:\/\/doi.org\/10.1136\/ard.2011.154211","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"4492_CR127","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/rheumatology\/keq108","volume":"49","author":"QY Choo","year":"2010","unstructured":"Choo QY, Ho PC, Tanaka Y, Lin HS (2010) Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-\u039aB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells. Rheumatology 49(8):1447\u20131460. https:\/\/doi.org\/10.1093\/rheumatology\/keq108","journal-title":"Rheumatology"},{"issue":"3","key":"4492_CR128","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.cellsig.2012.11.023","volume":"25","author":"CG Miao","year":"2013","unstructured":"Miao CG, Huang C, Huang Y et al (2013) MeCP2 modulates the canonical Wnt pathway activation by targeting SFRP4 in rheumatoid arthritis fibroblast-like synoviocytes in rats. Cell Signal 25(3):598\u2013608. https:\/\/doi.org\/10.1016\/j.cellsig.2012.11.023","journal-title":"Cell Signal"},{"issue":"1","key":"4492_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.13224","volume":"195","author":"C Steen-Louws","year":"2019","unstructured":"Steen-Louws C, Hartgring SAY, Popov-Celeketic J et al (2019) IL4-10 fusion protein: a novel immunoregulatory drug combining activities of interleukin 4 and interleukin 10. Clin Exp Immunol 195(1):1\u20139. https:\/\/doi.org\/10.1111\/cei.13224","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"4492_CR130","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cyto.2014.05.015","volume":"69","author":"A Thiolat","year":"2014","unstructured":"Thiolat A, Denys A, Petit M et al (2014) Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice. Cytokine 69(1):87\u201393. https:\/\/doi.org\/10.1016\/j.cyto.2014.05.015","journal-title":"Cytokine"},{"issue":"23","key":"4492_CR131","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1016\/j.febslet.2011.05.020","volume":"585","author":"A Ceribelli","year":"2011","unstructured":"Ceribelli A, Nahid MA, Satoh M, Chan EKL (2011) MicroRNAs in rheumatoid arthritis. FEBS Lett 585(23):3667\u20133674. https:\/\/doi.org\/10.1016\/j.febslet.2011.05.020","journal-title":"FEBS Lett"},{"issue":"1","key":"4492_CR132","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/biomedicines8010009","volume":"8","author":"AG Therapy","year":"2020","unstructured":"Therapy AG, Deviatkin AA, Vakulenko YA, Akhmadishina LV, Tarasov VV (2020) Emerging concepts and challenges in rheumatoid. Biomedicines 8(1):9","journal-title":"Biomedicines"},{"issue":"22","key":"4492_CR133","doi-asserted-by":"publisher","first-page":"12170","DOI":"10.3390\/ijms222212170","volume":"22","author":"M Payet","year":"2021","unstructured":"Payet M, Dargai F, Gasque P, Guillot X (2021) Epigenetic regulation (Including micro-rnas, dna methylation and histone modifications) of rheumatoid arthritis: a systematic review. Int J Mol Sci 22(22):12170. https:\/\/doi.org\/10.3390\/ijms222212170","journal-title":"Int J Mol Sci"},{"issue":"14","key":"4492_CR134","first-page":"4581","volume":"22","author":"J Li","year":"2018","unstructured":"Li J, Song Q, Shao L, Zhang LL, Guo XH, Mao YJ (2018) MiR-124A inhibits proliferation and invasion of rheumatoid arthritis synovial fibroblasts. Eur Rev Med Pharmacol Sci 22(14):4581\u20134588","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"4492_CR135","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s13577-017-0179-5","volume":"31","author":"Y Ye","year":"2018","unstructured":"Ye Y, Gao X, Yang N (2018) LncRNA ZFAS1 promotes cell migration and invasion of fibroblast-like synoviocytes by suppression of miR-27a in rheumatoid arthritis. Hum Cell 31(1):14\u201321. https:\/\/doi.org\/10.1007\/s13577-017-0179-5","journal-title":"Hum Cell"},{"issue":"10","key":"4492_CR136","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1172\/JCI97965","volume":"128","author":"Y Zou","year":"2018","unstructured":"Zou Y, Xu S, Xiao Y et al (2018) Long noncoding RNA LERFS negatively regulates rheumatoid synovial aggression and proliferation. J Clin Invest 128(10):4510\u20134524. https:\/\/doi.org\/10.1172\/JCI97965","journal-title":"J Clin Invest"},{"issue":"12","key":"4492_CR137","doi-asserted-by":"publisher","first-page":"22477","DOI":"10.1002\/jcp.28811","volume":"234","author":"X Shui","year":"2019","unstructured":"Shui X, Chen S, Lin J, Kong J, Zhou C, Wu J (2019) Knockdown of lncRNA NEAT1 inhibits Th17\/CD4+ T cell differentiation through reducing the STAT3 protein level. J Cell Physiol 234(12):22477\u201322484. https:\/\/doi.org\/10.1002\/jcp.28811","journal-title":"J Cell Physiol"},{"issue":"1","key":"4492_CR138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-015-0240-9","volume":"6","author":"J Zhang","year":"2015","unstructured":"Zhang J, Huang X, Wang H et al (2015) The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy. Stem Cell Res Ther 6(1):1\u20137. https:\/\/doi.org\/10.1186\/s13287-015-0240-9","journal-title":"Stem Cell Res Ther"},{"key":"4492_CR139","unstructured":"Causton B, Pardo-Saganta A, Gillis J et al (1998) Page 1 of 47 1. 409"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-022-04492-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-022-04492-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-022-04492-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T17:10:19Z","timestamp":1673543419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-022-04492-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":139,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["4492"],"URL":"https:\/\/doi.org\/10.1007\/s11010-022-04492-3","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"assertion":[{"value":"1 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}]}}